References
Sinclair JM, Chambers SE, Shiles CJ, Baldwin DS. Safety and tolerability of pharmacological treatment of alcohol dependence: comprehensive review of evidence. Drug Saf. 2016;39(7):627–45.
Braillon A, Granger B. Nalmefene and alcohol dependence: a new approach or the same old unacceptable marketing? Subst Abuse Rehabil. 2015;6:75–80.
Palpacuer C, Laviolle B, Boussageon R, Reymann JM, Bellissant E, Naudet F. Risks and benefits of nalmefene in the treatment of adult alcohol dependence: a systematic literature review and meta-analysis of published and unpublished double-blind randomized controlled trials. PLoS Med. 2015;12(12):e1001924.
Braillon A. Nalmefene in alcohol misuse: junk evaluation by the European Medicines Agency. BMJ. 2014;348:g2017.
Spence D. Bad medicine: nalmefene in alcohol misuse. BMJ. 2014;348:g1531.
Naudet F, Granger B, Braillon A. Cost-effectiveness of nalmefene: exaggerated expectations or fallacy? Alcohol Alcohol. 2016. doi:10.1093/alcalc/agw029 (Online Jun 3)
Fitzgerald N, Angus K, Elders A, de Andrade M, Raistrick D, Heather N, McCambridge J. Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers. Addiction. 2016;111(8):1477–87. doi:10.1111/add.13438
Muckle W, Muckle J, Welch V, Tugwell P. Managed alcohol as a harm reduction response for alcohol addiction in populations at high risk for substance abuse. Cochrane Database Syst Rev. 2012;12:CD006747.
Rivollier F, Masson M. Manic symptoms induced by high doses of baclofen: a case report. Encephale. 2016. doi:10.1016/j.encep.2016.03.015 (Online Jun 9).
Olivier PY, Joyeux-Faure M, Gentina T, Launois SH, d’Ortho MP, Pépin JL, Gagnadoux F. Severe central sleep apnea associated with chronic baclofen therapy: a case series. Chest. 2016;149(5):e127–31.
Braillon A, Lexchin J. Off-label drug use: whose interests are served? Am J Med Qual. 2016;31(3):285.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
No sources of funding were used in the preparation of this letter.
Conflict of interest
Alain Braillon has no conflicts of interest that are directly relevant to the content of this letter.
Rights and permissions
About this article
Cite this article
Braillon, A. Comment on: “Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence”. Drug Saf 39, 1151–1152 (2016). https://doi.org/10.1007/s40264-016-0447-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40264-016-0447-4